503A or 503BKnowing When to Order from Each One Epicur Pharma BPC 157 SolXGenix The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides for Pharmacies: How to Prepare for BPC 157, Category 1 Changes & What to Do Now (Webinar) What is a 503B outsourcing facility, and why are so many of them uninspected by FDA? Partnership for Safe Medicines Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #